TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31213443

Group type: EXPERIMENTAL
Intervention: FES cycling and goal-directed functional exercises with a physiotherapist, plus recreational cycling at home, for 8 weeks (2 sessions per week).
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care (waitlist control group).
Number of subjects: 40
Study: 28778829

Group type: EXPERIMENTAL
Intervention: Portable powered ankle-foot orthosis (PPAFO)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Passive ankle-foot orthosis (AFO)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Shoes (no AFO)
Number of subjects: 16
Study: 27020487

Group type: EXPERIMENTAL
Intervention: Prophylactic intravenous ephedrine 10mg (Group E)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Ondansetron 8mg (Group O)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Normal saline (Group P)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Group E and Group O
Number of subjects: 168
Study: 23702697

Group type: EXPERIMENTAL
Intervention: IVIG (1-2 g/kg, over 2 days)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 15

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 15
Study: 22884767

Group type: EXPERIMENTAL
Intervention: Exenatide QW (2 mg)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Insulin glargine (starting dose, 4 U)
Number of subjects: 427
Study: 21344812

Group type: EXPERIMENTAL
Intervention: Calf stretching box
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional exercise method
Number of subjects: 80
Study: 18041508

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control
Number of subjects: 240
Study: 16044784

Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM) methods of comparison
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognition-based medicine (CBM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomised controlled trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meta-analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complementary approach of different evaluation methods
Number of subjects: 0
Study: 12898879

Group type: EXPERIMENTAL
Intervention: Traditional nursing model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modern nursing model (nursing process)
Number of subjects: 0
Study: 10524884

Group type: COMPARATOR
Intervention: 4 mg doxazosin
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 8 mg doxazosin
Number of subjects: 82
Study: 7696941

Group type: EXPERIMENTAL
Intervention: 60 mg aspirin daily
Number of subjects: 9364

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 9364
Study: 2045466

Group type: EXPERIMENTAL
Intervention: High fat modern diet (carbohydrate 30%, fat 50%, protein 20%)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Traditional Pima diet (carbohydrate 70%, fat 15%, protein 15%)
Number of subjects: 24
Study: 7043753

Group type: EXPERIMENTAL
Intervention: CMFVP (cyclophosphamide + methotrexate + fluoro‐uracil + vincristine + prednisone)
Number of subjects: 81

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide + methotrexate + fluoro‐uracil)
Number of subjects: 81

Group type: COMPARATOR
Intervention: CMF + MER (immunotherapy with methanol extract residue of BCG)
Number of subjects: 81
Study: 30993573

Group type: EXPERIMENTAL
Intervention: Bariatric surgery in patients aged ≥ 60 years (case group)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Bariatric surgery in patients aged ≤ 50 years (control group)
Number of subjects: 216
Study: 29784470

Group type: EXPERIMENTAL
Intervention: MenACWY-TT (3+1 schedule at ages 2, 4, 6 and 15-18 months)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: MenACWY-TT (1+1 schedule at 6 and 15-18 months)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: MenACWY-TT (single-dose at 15-18 months)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: MenACWY-TT (all groups)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Routine childhood vaccines (PHiD-CV and DTPa-IPV/Hib)
Number of subjects: 750

Group type: COMPARATOR
Intervention: All groups (MenACWY-TT and routine vaccines)
Number of subjects: 750
Study: 27569651

Group type: EXPERIMENTAL
Intervention: 20 mg hydrocortisone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 24686957

Group type: EXPERIMENTAL
Intervention: Self-affirmation intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-affirmation condition
Number of subjects: 80
Study: 22903909

Group type: EXPERIMENTAL
Intervention: Group music therapy for 10 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no intervention during the study)
Number of subjects: 17
Study: 20524885

Group type: EXPERIMENTAL
Intervention: Mood-management intervention
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (no mood-management tool)
Number of subjects: 1000
Study: 17884598

Group type: EXPERIMENTAL
Intervention: Implicit self-comparisons against self at an earlier time, against healthy peers, or against ill patients
Number of subjects: 0
Study: 15686573

Group type: EXPERIMENTAL
Intervention: Correlated linguistic cues
Number of subjects: 0

Group type: COMPARATOR
Intervention: No correlated linguistic cues
Number of subjects: 0
Study: 12088814

Group type: EXPERIMENTAL
Intervention: 7% sevoflurane with 50% N(2)O
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous midazolam 0.1 mg/kg followed by 7% sevoflurane with 50% N(2)O
Number of subjects: 40
Study: 9569075

Group type: EXPERIMENTAL
Intervention: Intramuscular methylprednisolone acetate (i.m. MP) 120 mg 3-weekly
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral prednisolone (OP) initial dose 15 mg, gradually tapering
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intramuscular methylprednisolone acetate (i.m. MP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral prednisolone (OP)
Number of subjects: 60
Study: 8547555

Group type: EXPERIMENTAL
Intervention: 20 mg of intrapleural morphine (IPM group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: 20 mg of intravenous morphine (IVM group)
Number of subjects: 28
Study: 2797892

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 523421

Group type: EXPERIMENTAL
Intervention: Ethambutol (25 mg/kg daily) for 8 days in healthy subjects
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ethambutol plus isoniazid plus rifampicin for 6 months
Number of subjects: 46

Group type: COMPARATOR
Intervention: Streptomycin plus isoniazid plus PAS for 3 months, then streptomycin plus isoniazid plus ethambutol for another 3 months
Number of subjects: 46
Study: 31896529

Group type: EXPERIMENTAL
Intervention: Antidepressant medications (ADM)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Both Antidepressant medications (ADM) and Cognitive therapy (CT)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Cognitive therapy (CT)
Number of subjects: 433
Study: 30611343

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 15 mg/kg of tranexamic acid (TXA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no TXA)
Number of subjects: 80
Study: 28278717

Group type: EXPERIMENTAL
Intervention: Directly observed therapy (DOT) with intermittent, high-dose Vitamin D3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 0
Study: 25443996

Group type: EXPERIMENTAL
Intervention: Exercise in addition to usual care (n=39): 12-week exercise programme involving three, 30-min resistance-training sessions/week and a pedometer-based walking programme.
Number of subjects: 81

Group type: COMPARATOR
Intervention: Usual care (n=42): psychotherapy, pharmaceutical interventions, and group therapy.
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Exercise in addition to usual care (n=39)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Usual care (n=42)
Number of subjects: 81
Study: 23879277

Group type: EXPERIMENTAL
Intervention: 150 ms AVD
Number of subjects: 31

Group type: COMPARATOR
Intervention: Minimizing right ventricular pacing (MRVP)
Number of subjects: 31
Study: 21283981

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 280
Study: 19760753

Group type: EXPERIMENTAL
Intervention: Phlebotomies to obtain a ferritin level <50 ng/mL followed by pegylated‐Interferon alpha2b + ribavirin
Number of subjects: 33

Group type: COMPARATOR
Intervention: Pegylated‐Interferon alpha2b + ribavirin
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Phlebotomies
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Phlebotomies and antiviral therapy
Number of subjects: 33
Study: 16720167

Group type: EXPERIMENTAL
Intervention: Endoscopic surgery
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Stereotactic aspiration
Number of subjects: 90

Group type: COMPARATOR
Intervention: Craniotomy
Number of subjects: 90
Study: 15592115

Group type: EXPERIMENTAL
Intervention: Acuvue 2
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Acuvue Advance
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Focus Night & Day
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (no lenses)
Number of subjects: 62
Study: 11693012

Group type: EXPERIMENTAL
Intervention: Preventive dental program (PDP)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 136
Study: 9389947

Group type: EXPERIMENTAL
Intervention: Clindamycin hydrochloride capsules, 150 mg by mouth four times daily for 7 consecutive days.
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo (partner treatment).
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Clindamycin hydrochloride capsules, 150 mg by mouth four times daily for 7 consecutive days (among women cured by the first week's visit).
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo (partner treatment, among women cured by the first week's visit).
Number of subjects: 139
Study: 7707159

Group type: EXPERIMENTAL
Intervention: Twice a day slow-release nifedipine
Number of subjects: 113

Group type: COMPARATOR
Intervention: Once a day amlodipine
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 113
Study: 2451968

Group type: EXPERIMENTAL
Intervention: Dextran 70 and Dihydroergotamine (DHE)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Dextran 70 alone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study: 29100903

Group type: EXPERIMENTAL
Intervention: Antibiotics (n=34)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo (n=34)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Antibiotics (n=32)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo (n=30)
Number of subjects: 122
Study: 27353441

Group type: EXPERIMENTAL
Intervention: Demineralized freeze-dried bone allograft (DFDBA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 36
Study: 25802953

Group type: EXPERIMENTAL
Intervention: Strengthening exercise group (n = 15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Proprioceptive-balance exercise group (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intergroup analysis between strengthening and proprioceptive-balance exercise groups
Number of subjects: 30
Study: 23876062

Group type: EXPERIMENTAL
Intervention: Capecitabine (1000 mg/m2 orally BID, days 1 to 14 of 21) in combination with Sorafenib (600 mg/day orally BID, days 1 to 21)
Number of subjects: 519

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Capecitabine and Sorafenib
Number of subjects: 519
Study: 21070639

Group type: EXPERIMENTAL
Intervention: Combined physical exercise and psychosocial intervention program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 100
Study: 18180683

Group type: EXPERIMENTAL
Intervention: Cyclosporine 0.05% ophthalmic emulsion (Restasis; Allergan, Inc.) used twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group receiving rewetting drops (Refresh Preservative Free Artificial Tears; Allergan, Inc.) used twice daily
Number of subjects: 0
Study: 16595148

Group type: EXPERIMENTAL
Intervention: Cisplatin/cyclophosphamide
Number of subjects: 101
Study: 15192065

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 800 microg
Number of subjects: 154

Group type: COMPARATOR
Intervention: Curettage
Number of subjects: 154
Study: 11729030

Group type: EXPERIMENTAL
Intervention: 3 g/day ethyl eicosapentaenoic acid (EPA)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 9209567

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 31
Study: 8269914

Group type: EXPERIMENTAL
Intervention: Thiamine (50 mg/day)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Folate (5 mg/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both vitamins (Thiamine and Folate)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (two tablets per day)
Number of subjects: 72
Study: 2957348

Group type: EXPERIMENTAL
Intervention: Teicoplanin 400 mg intravenous bolus
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (no intervention specified)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Amoxycillin 1.0 g intramuscularly
Number of subjects: 120
Study: 30033356

Group type: EXPERIMENTAL
Intervention: Lorcaserin 10mg, twice a day for 24 weeks
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 27448283

Group type: EXPERIMENTAL
Intervention: Intra-articular platelet-rich plasma (PRP)
Number of subjects: 315
Study: 25418542

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program using the Japanese-style healthy plate (n=10)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Waiting-list control group (n=9)
Number of subjects: 19
Study: 22658268

Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT) + Specific Exercises (SE)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Specific Exercises (SE)
Number of subjects: 19
Study: 21142633

Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle modification with incorporation of the DASH diet
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle modification aimed at weight loss, increased exercise and dietary sodium reduction
Number of subjects: 810

Group type: COMPARATOR
Intervention: Advice only
Number of subjects: 810
Study: 18838727

Group type: EXPERIMENTAL
Intervention: Quality improvement collaborative (n = 22 hospitals)
Number of subjects: 4400

Group type: COMPARATOR
Intervention: Comparative feedback report (control group, n = 22 hospitals)
Number of subjects: 4400
Study: 15635615

Group type: EXPERIMENTAL
Intervention: MMP-9 in induced sputum from CF children
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MMP-9/TIMP-1 molar ratio in CF children
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MMP-9 levels in CF children
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sputum MMP-9 and TIMP-1 concentrations in CF children
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MMP-9 and TIMP-1 correlation with airway infection
Number of subjects: 18
Study: 12075231

Group type: EXPERIMENTAL
Intervention: ThinPrep technique
Number of subjects: 209

Group type: COMPARATOR
Intervention: Conventional smear technique
Number of subjects: 209
Study: 9459075

Group type: EXPERIMENTAL
Intervention: Self-regulation task (expressing thoughts and feelings about entering college and formulating coping plans)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Disclosure task (expressing thoughts and feelings only)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control task (writing about trivial topics)
Number of subjects: 122
Study: 7829604

Group type: EXPERIMENTAL
Intervention: GH treatment (0.2 IU/kg.week for 6 months)
Number of subjects: 22
Study: 2371372

Group type: EXPERIMENTAL
Intervention: Adjunctive imipramine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 334471

Group type: EXPERIMENTAL
Intervention: 150 mg flurbiprofen
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 600 mg phenylbutazone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2.1 g aspirin
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 31916473

Group type: EXPERIMENTAL
Intervention: PRC-063 (16-hr multilayer-release methylphenidate)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study: 31898531

Group type: EXPERIMENTAL
Intervention: Plasma-Lyte
Number of subjects: 66

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 66
Study: 31104056

Group type: EXPERIMENTAL
Intervention: Vitamin D 2,000 IU tablet every other day for 12 weeks
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 28540483

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 217

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 217
Study: 26608559

Group type: EXPERIMENTAL
Intervention: Stigma reduction intervention
Number of subjects: 1760
Study: 23626006

Group type: EXPERIMENTAL
Intervention: rhGH
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (untreated group)
Number of subjects: 30
Study: 21304091

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) plus optimal medical therapy (OMT)
Number of subjects: 2287

Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT) alone
Number of subjects: 2287
Study: 19187813

Group type: EXPERIMENTAL
Intervention: Residential Cognitive Therapy (RCT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Residential Interpersonal Psychotherapy (RIPT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cognitive variables (self‐focus, estimated probability and cost of negative social events, safety behaviors)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Interpersonal variable (perceived acceptance by others)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Social anxiety
Number of subjects: 80
Study: 16957058

Group type: EXPERIMENTAL
Intervention: Rapid palatal expansion (RPE)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 45
Study: 15060509

Group type: EXPERIMENTAL
Intervention: lopinavir (400 mg twice daily) and ritonavir (100 mg twice daily)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: amprenavir (600 mg twice daily) plus ritonavir (100 mg twice daily)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: lopinavir (400 mg twice daily) and ritonavir (100 mg twice daily) plus additional ritonavir (100 mg twice daily)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: amprenavir (600 mg twice daily) plus ritonavir (200 mg twice daily)
Number of subjects: 27
Study: 11456011

Group type: EXPERIMENTAL
Intervention: Lodoxamide 0.1% ophthalmic solution
Number of subjects: 95

Group type: COMPARATOR
Intervention: Levocabastine 0.05% ophthalmic suspension
Number of subjects: 95
Study: 9917590

Group type: EXPERIMENTAL
Intervention: Polished stems
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Matte surfaced stems with metal centralizers
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Polished modular stems
Number of subjects: 80

Group type: COMPARATOR
Intervention: Matte finish stems
Number of subjects: 80
Study: 7805637

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 364

Group type: COMPARATOR
Intervention: Control
Number of subjects: 364
Study: 2968262

Group type: EXPERIMENTAL
Intervention: CMF + MAP
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: MAP h.d.
Number of subjects: 289

Group type: COMPARATOR
Intervention: MAP + CMF
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: MAP
Number of subjects: 289
Study: 1101844

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 80
Study: 31180819

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with oral tegafur-uracil
Number of subjects: 991

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 991
Study: 28560194

Group type: EXPERIMENTAL
Intervention: Controlled suction pressure at 400 mmHg and operation time less than 75 s
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group with suction pressure ranging from 400-500 mmHg
Number of subjects: 300
Study: 25707402

Group type: EXPERIMENTAL
Intervention: Higher 25-hydroxyvitamin D (25OHD) levels
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Higher 1,25-dihydroxyvitamin D (1,25(OH)2 D) levels
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Lowest 1,25(OH)2 D levels (8.70 to 51.60 pg/mL)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Adjustment of 1,25(OH)2 D data for 25OHD
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Higher 1,25(OH)2 D levels with BMD adjustment
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: 25OHD vs 1,25(OH)2 D
Number of subjects: 1000
Study: 22077318

Group type: EXPERIMENTAL
Intervention: Detoxified Jatropha kernel meal (DJKM) diet (J(50))
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control diet (fish meal and wheat meal, without DJKM and SBM)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Soybean meal (SBM) diet (S(50))
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: DJKM diet (J(75))
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: SBM diet (S(75))
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 180
Study: 21878826

Group type: EXPERIMENTAL
Intervention: 3-question version of the Edinburgh Postpartum Depression Scale (EPDS)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Full EPDS
Number of subjects: 195

Group type: COMPARATOR
Intervention: Provider impression of maternal depressive symptoms
Number of subjects: 195
Study: 19622108

Group type: EXPERIMENTAL
Intervention: Rectal diclofenac 100 mg (Group 1, n = 19)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo suppository (Group 2, n = 18)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Rectal diclofenac (Group 1)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (Group 2)
Number of subjects: 37